San Diego, California, United States, November 20, 2026
Belite Bio, Inc. has announced that the U.S. Food and Drug Administration (FDA) has extended its review period for the New Drug Application (NDA) of tinlarebant, an investigational oral drug candidate being developed for Stargardt disease type 1 (STGD1). The agency has extended the review timeline by three months, establishing May 12, 2027, as the revised Prescription Drug User Fee Act (PDUFA) action date. The company said the FDA requires additional time to review information submitted in support of the application. The agency also indicated that, provided no major deficiencies are identified during the ongoing review, it plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, to Belite Bio by April 12, 2027. The regulatory update marks a change to the expected decision timeline for the company’s lead drug candidate, which is being developed to address an important unmet medical need in inherited retinal disease. Belite Bio stated that it remains committed to working with the FDA throughout the review process and expressed confidence in the clinical evidence supporting tinlarebant.
FDA Extends NDA Review Timeline to May 2027
The three-month extension gives the FDA additional time to evaluate the information submitted as part of the tinlarebant NDA. The revised PDUFA action date is May 12, 2027, while the agency’s anticipated communication regarding proposed labeling and potential postmarketing requirements is scheduled for April 12, 2027, provided no major deficiencies emerge during the review. This communication is conditional and does not mean that the application has been approved or that final product labeling has been agreed. The FDA’s review remains ongoing, and the agency will determine whether the submitted evidence supports marketing authorisation for the proposed indication. For Belite Bio, the extended timeline represents an important regulatory milestone as it continues its efforts to advance tinlarebant toward potential commercial availability. The company has highlighted the need for new treatment options for people living with Stargardt disease, for which there are currently limited therapeutic options. The extension should not be interpreted as a regulatory rejection or a finding that the drug has failed to demonstrate efficacy. The company has not identified a specific deficiency as the reason for the additional review time in this announcement.
Tinlarebant Targets Vitamin A-Related Retinal Damage
Tinlarebant, also known as LBS-008, is an investigational oral therapy designed to reduce the accumulation of harmful vitamin A-derived compounds called bisretinoids in the retina. These compounds are associated with retinal damage and disease progression in Stargardt disease type 1. Bisretinoids form as by-products of the visual cycle, a biological process involving vitamin A, or retinol, that is essential for vision. Tinlarebant is designed to reduce and maintain levels of serum retinol-binding protein 4 (RBP4), the principal carrier responsible for transporting retinol from the liver to the eye. By modulating retinol transport and reducing the amount of vitamin A entering the eye, the drug candidate aims to limit the formation and accumulation of bisretinoids. This mechanism is intended to address an underlying contributor to retinal degeneration rather than simply manage symptoms. In addition to Stargardt disease type 1, Belite Bio is investigating tinlarebant in geographic atrophy, an advanced form of dry age-related macular degeneration. However, the current NDA under FDA review relates specifically to Stargardt disease type 1.
Clinical Development and Regulatory Milestones
Belite Bio has advanced tinlarebant through a clinical development programme focused on inherited and degenerative retinal conditions. The company reported that its global Phase 3 DRAGON trial in adolescent and adult participants with Stargardt disease type 1 was completed and met its primary endpoint. The company is also evaluating the candidate in the Phase 2/3 DRAGON II trial involving adolescent and adult participants with STGD1. Separately, the Phase 3 PHOENIX trial is investigating tinlarebant in participants with geographic atrophy. These studies form part of the company’s broader effort to evaluate the potential of the drug candidate across retinal diseases associated with bisretinoid accumulation. Tinlarebant has received several regulatory designations in the United States, including Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for Stargardt disease type 1. It has also received regulatory designations in other markets. Such designations may provide development or review-related benefits, but they do not guarantee marketing approval. The FDA’s ongoing NDA assessment will determine whether the available evidence supports approval for the proposed indication. The revised action date of May 12, 2027, is therefore an important upcoming milestone for Belite Bio and the Stargardt disease community.
Source: Belite Bio press release



